Identification of novel bacterial topoisomerase inhibitors
The Barbachyn group is currently focused on the discovery and development of a novel class of bacterial topoisomerase inhibitors that will hopefully have clinical utility in treating serious infections caused by sensitive and multidrug-resistant Gram-negative bacteria. A close collaboration with the Walter Reed Army Institute of Research (WRAIR) is a key component of the overall research plan.Bacterial resistance to currently available antimicrobial agents continues to be a growing threat to public health. The CDC recently reported that each year in the United States at least 2 million people acquire serious infections caused by bacteria resistant to one or more antibacterial agents, with 23,000 of them dying as a direct result. Many more die from underlying medical conditions that are exacerbated by these antibiotic-resistant (ABR) infections.
- Course code: